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AbstrAct
Objective To review clinical and investigation findings 
in patients referred to a specialist prion clinic who were 
suspected to have sporadic Creutzfeldt-Jakob disease 
(sCJD) and yet were found to have an alternative final 
diagnosis.
Methods Review the clinical findings and investigations 
in 214 patients enrolled into the UK National Prion 
Monitoring Cohort Study between October 2008 and 
November 2015 who had postmortem confirmed sCJD 
and compare these features with 50 patients referred 
over the same period who had an alternative final 
diagnosis (CJD mimics).
results Patients with an alternative diagnosis and 
those with sCJD were of similar age, sex and frequency 
of dementia but CJD mimics had a longer clinical 
history. Myoclonus, rigidity and hallucinations were 
more frequent in patients with sCJD but these features 
were not helpful in classifying individual patients. 
Alzheimer’s disease, dementia with Lewy bodies and 
genetic neurodegenerative disorders were alternative 
diagnoses in more than half of the CJD mimic cases, 
and 10% had an immune-mediated encephalopathy; 
lymphoma, hepatic encephalopathy and progressive 
multifocal leukoencephalopathy were seen more than 
once. Diffusion-weighted MRI was the most useful 
readily available test to classify cases correctly (92% 
CJD, 2% CJD mimics). The CSF cell count, 14-3-3 protein 
detection and S100B were of limited value. A positive 
CSF RT-QuIC test, introduced during the course of the 
study, was found in 89% of tested CJD cases and 0% 
CJD mimics.
conclusion The combination of diffusion-weighted MRI 
analysis and CSF RT-QuIC allowed a perfect classification 
of sCJD versus its mimics in this study.
IntrOductIOn
Although there is no consensus definition for clinical 
practice, rapidly progressive dementia is commonly 
considered to comprise a cognitive disorder with 
progression to advanced stages or death in less than 
2 years. Sporadic Creutzfeldt-Jakob disease (sCJD), 
the most common form of human prion disease, 
is the prototypic diagnosis of the group, but the 
differential is wide and includes several treatable 
disorders. Because of a concern about the poten-
tial for iatrogenic spread and zoonoses, specialist 
prion disease assessment centres are found in many 
countries and are referred cases suspected to have 
sCJD and have developed experience in differenti-
ating these from other causes of rapidly progressive 
dementia.
Among the numerous case reports and series, the 
two most significant analyses specifically addressing 
the problem of patients initially diagnosed with 
sCJD who subsequently had an alternative diag-
nosis originate from USA and UK.1 2 Historically, 
clinicians have relied on the EEG and abnormal 
CSF proteins in diagnosing CJD, while being aware 
that these tests were not highly specific. Since these 
two papers were published, the imaging features 
of sCJD have been better characterised and use 
of diffusion-weighted images has become more 
universal, enabling the clinician to have greater 
certainty when diagnosing sCJD.3 4 Nevertheless, in 
spite of the high sensitivity of MRI in the diagnosis 
of sCJD, the typical findings are frequently not 
mentioned in the initial radiology report.5
Prion diseases are caused by misfolding of a 
membrane anchored protein, PrPC, into abnormal 
forms, including proteinase resistant forms (PrPSc) 
and forms which act as a template for PrPC inducing 
generation of more abnormal PrP.6 Capitalising 
on the templated misfolding mechanism, assays 
have been developed to detect minute amounts 
of abnormal PrP that involve cycles of sonication 
or shaking and incubation with PrPc followed by 
detection of abnormal PrP by Western blot or thio-
flavin T binding (PMCA, RT-QuIC).7 8 Increasingly 
the results of the cerebrospinal fluid RT-QuIC assay 
have been incorporated in epidemiological diag-
nostic criteria.9 10
In this paper, we review the clinical experience 
of the UK NHS National Prion Clinic in assessment 
of a large number of patients referred with a provi-
sional diagnosis of sCJD. We compare the clinical 
and investigative features of those who subsequently 
were proven to have sCJD at autopsy with those 
who did not have prion disease and the relative 
merits of clinical features, imaging, CSF analysis 
and other tests in classifying patients correctly.
MethOds
Since 2004, patients with a provisional diagnosis 
of prion disease who are resident in the UK are 
referred jointly to National CJD Research and 
Surveillance Unit (Edinburgh, UK) and National 
Prion Clinic (London, UK). In 2008, the National 
Prion Monitoring Cohort Study, hereafter called 
the ‘Cohort Study’, was established; it is an obser-
vational longitudinal study of all patients with, or 
at risk of, developing human prion disease of any 
type.11 All patients are invited to take part in the 
Cohort Study, which involves review by a member 
of the National Prion Clinic (consultant neurologist 
or clinical research fellow) and collection of clinical 
ReSeARCh PAPeR
Imaging and CSF analyses effectively distinguish CJD 
from its mimics
Peter Rudge,1,2 harpreet hyare,2 Alison Green,3 John Collinge,1,2 Simon Mead1,2
neurodegeneration
to cite: Rudge P, hyare h, 
Green A, et al. J Neurol 
Neurosurg Psychiatry 
Published Online First: [please 
include Day Month Year]. 
doi:10.1136/jnnp-2017-
316853
1MRC Prion Unit at UCL, UCL 
Institute of Prion Diseases, 
London, UK
2NhS National Prion Clinic, UCL 
hospitals NhS Foundation Trust, 
London, UK
3The National CJD Research 
and Surveillance Unit, Western 
General hospital, London, UK
correspondence to
Dr Peter Rudge, NhS National 
Prion Clinic, National 
hospital for Neurology and 
Neurosurgery, University College 
London hospitals NhS Trust, 
London NW1 2BU, UK;  p. 
rudge@ prion. ucl. ac. uk
Received 11 July 2017
Revised 20 September 2017
Accepted 19 October 2017
 JNNP Online First, published on November 15, 2017 as 10.1136/jnnp-2017-316853
Copyright Article author (or their employer) 2017. Produced by BMJ Publishing Group Ltd under licence. 
group.bmj.com on December 11, 2017 - Published by http://jnnp.bmj.com/Downloaded from 
2 Rudge P, et al. J Neurol Neurosurg Psychiatry 2017;0:1–6. doi:10.1136/jnnp-2017-316853
neurodegeneration
data including physical examination findings, blood tests, neuro-
psychology, neurophysiology and MRI at regular intervals 
depending on the type of prion disease.
In this paper, we review the 606 patients thought on clin-
ical grounds to have prion disease or be at risk of developing 
prion disease who were referred to the National Prion Clinic 
and enrolled into the Cohort study between October 2008 and 
November 2015 (see flow chart in figure 1). Of these, 440 were 
referred with a clinical diagnosis of suspected sCJD or any other 
sporadic human prion disease (eg, sporadic fatal insomnia and 
variably protease sensitive prionopathy). We also included those 
suspected to have prion disease even though the clinical duration 
was longer than 2 years. A total of 232 (53%) had an autopsy 
or cerebral biopsy and 214 were proven to have sCJD and 18 
an alternative diagnosis. 208 did not have histological examina-
tion of the brain; 171 patients fulfilled the criteria for probable 
sCJD and 32 had on clinical and investigative grounds an alter-
native diagnosis. Five additional patients in this group were lost 
to follow-up.
In this paper, we compared the clinical and investigative 
features of the 214 definite cases of sCJD with the 50 cases with 
an alternative diagnosis. None of the 197/214 patients in whom 
the PRNP gene was sequenced had a mutation. All the patients 
were initially investigated by the referring clinician and virtually 
all patients had at least one MRI of the brain, usually 1.5T, but 
sequences varied. The presenting MRI study was reviewed by an 
experienced neuroradiologist (HH) and an experienced neurol-
ogist (PR) and consensus findings were documented. Restricted 
diffusion in the basal ganglia (caudate, putamen), thalamus and 
cortex (frontal, parietal, temporal, occipital, insula) was assessed 
and the presence of atrophy was documented. Finally, any other 
findings such as white matter lesions and contrast enhancement 
were noted. CSF was examined in 182 patients and neurode-
generative markers (14-3-3, S100B) sought in 132 patients; 
RT-QuIC, a technique not in routine clinical use during the early 
part of the study, was obtained in 75 cases. An EEG report was 
obtained in 186 patients; in most of these, serial recording was 
not obtained. Because of the nature of the referrals from other 
clinicians inevitably there was variation in what other investiga-
tions were undertaken. Clinical notes were reviewed and data 
collected on neuronal and paraneoplastic antibodies, which we 
would routinely recommend.
Comparisons between groups were made using Student’s 
t-test, χ² or Fisher’s exact test as appropriate (SPSS, IBM).
results
A total of 55 patients referred as suspected cases of sCJD ulti-
mately had an alternative diagnosis to CJD; 26 had a definite 
alternative diagnosis, 24 had met established consensus clinical 
criteria for an alternative diagnosis and 5 were lost to follow-up. 
A total of 214 patients had a definite diagnosis of sCJD at post-
mortem examination. The demographic features and time to 
referral of these patients are shown in table 1.
The age and sex ratio in the definite patients with CJD and 
those with an alternative diagnosis were similar. Interestingly, 
the time before a referral was made to the clinic was much 
greater in those patients who did not have CJD (8.8 months vs 
18.8 months, t-test, P<0.0001).
The most frequent diagnosis was of an alternative neuro-
degenerative disease, nearly 60% (28 patients) having Alzhei-
mer’s disease (AD) or dementia with Lewy bodies (DLB). The 
remainder had a variety of other diseases. In 26 patients, the 
diagnosis was considered certain on the basis of autopsy or 
definitive laboratory tests and in 24 probable on the basis of 
clinical picture and investigations.
cases with a definite alternative diagnosis
Eight patients were proven to have AD at autopsy, two of whom 
had in addition minor vascular disease (Table 2). Three were 
shown at autopsy to have DLB, two of whom had in addition 
minor vascular disease and one minor AD pathology.
A variety of other definitive diagnoses were made. In six 
patients in whom autopsies were done two had progressive multi-
focal leukoencephalopathy (PML), two a cerebral lymphoma, 
one encephalitis of unknown cause and one hepatic encephalop-
athy. Nineadditional patients who did not have an autopsy were 
proven to have an alternative diagnosis. Five had an autoimmune 
encephalopathy due to high titres of Leucine-rich, glioma-inac-
tivated antibodies-1 (LGI1; three cases), N-methyl-D-aspartate 
antibodies (NMDA; one case) and glycine-1 receptor antibodies 
(Gly1R-Abs; one case). Four patients had a non-prion genetic 
cause for their disorder, two carrying hexanucleotide expansions 
in the C9orf72 gene, one CSF1R mutation (A781V) and one 
had a combination of beta thalassaemia major and alkaptonuria 
with a cognitive disorder that improved following withdrawal of 
nitisinone treatment.12 
Figure 1 Flow chart of recruitment of all cases suspected of prion 
disease referred to the National Prion Clinic from 2008 to 2015. Patients 
included in the current study shown in red. sCJD, sporadic Creutzfeldt-
Jakob disease.
table 1 Demographic features and referral delay in both groups of 
patients
diagnosis Age (years) sex ratio M/F
referral delay (months)
mean (median; range)*
sCJD 66.8 (39–85) 98/116 8.8 (3.3; 0.3–22.4)
Not CJD 65.9 (27–88) 22/28 18.8 (34.5; 1.5–108)**
*Note this is delay to referral, not the duration of cognitive decline which was rapid 
(<2 years) in all.
**P<0.0001.
CJD, Creutzfeldt-Jakob disease; sCJD, sporadic CJD.
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cases with a clinical diagnosis
The other 24 patients had good evidence of a clinical diagnosis 
other than prion disease. Probable DLB (10 patients) was diag-
nosed by prolonged survival, parkinsonian features, diurnal fluc-
tuating course, predominant visual hallucinations or profound 
rigidity on administration of dopamine antagonists13 and in two 
a positive DAT scan (Table 2). Probable AD (seven patients) was 
diagnosed from the prolonged clinical picture dominated by 
progressive memory impairment and posterior parietal symp-
toms, absence of other neurological signs, together with MRI 
(focal hippocampal/posterior parietal atrophy) and CSF markers 
indicating abnormalities of abeta and tau proteins.14 One patient 
had a frontotemporal dementia with evidence of anterior horn 
cell disease. Encephalitis (three patients) and stroke were diag-
nosed from the clinical picture and CSF, blood test results and 
MRI findings. The patient with hepatic encephalopathy had a 
spontaneous lienorenal shunt, raised serum ammonia level (106 
µmol/L), metal was detected in the lentiform nucleus on T1 
MRI, the EEG had abnormal sharpened complexes and there 
was improvement with shunt closure.
Features simulating scJd
The clinical features of the two groups of patients were docu-
mented in the Cohort Study systematic neurological history 
taking and examination (see table 3).
Progressive cognitive decline of less than 2 years duration is 
an absolute requirement for the diagnosis of probable sCJD and 
all but two definite sCJD cases in this series fulfilled that crite-
rion. However, in those patients with an alternative diagnosis, 
although nearly a 94% had cognitive decline, in a substantial 
proportion, the progression was slower as indicated by the delay 
in referral (table 1). Most clinicians are aware that patients with 
sCJD commonly have hallucinations and myoclonus and these 
were reported in 70%–80% of the present series. These symp-
toms were significantly less frequent in those with an alternative 
diagnosis occurring in about half the patients.
Rigidity of the limbs and neck are frequent findings in 
sCJD but in this series was also a feature in two-thirds of the 
patients with an alternative diagnosis. Given the frequency of 
these abnormalities in the patients with an alternative diagnosis, 
it is not surprising that the referring clinician had CJD in the 
differential diagnosis; it is in these patients that investigations 
proved so valuable.
Investigations
The results of brain imaging, CSF examination and EEG are 
shown in table 4.
Imaging
A total of 171 patients with definite sCJD and 47 patients with 
other diagnoses had at least one MRI available for review. Seven 
per cent of the patients with sCJD and 19% of the non-CJD 
cases had normal imaging (table 4A).
Generalised atrophy was less common in the patients with 
sCJD (40%) than in the non-prion cases (55%) (P=0.07) but the 
pattern of atrophy was frequently different. Atrophy was usually 
generalised in sCJD but it was focal in most neurodegenerative 
cases including 19 with AD and DLB involving the hippocampus 
and/or the posterior parietal area, especially in the former. 
Minor white matter abnormal signal on T2-weighted sequences 
reflecting vascular disease occurred in about 15% of both groups 
but extensive white matter abnormality was confined to seven 
non-prion cases (P<0.001); the diagnoses in these cases were 
SSPE, lymphoma, PML, CSF1R dementia, autoimmune enceph-
alitis and encephalitis of unknown cause.
The most striking difference between the scans of the two 
groups was on diffusion weighted sequences (table 4A). There 
was diffusion restriction in 92% cases of sCJD; 112 (66%) had 
restriction of diffusion in the basal ganglia and cortex, 13 (8%) 
had restriction in the basal ganglia alone (figure 2A–C) and 33 
(19%) had restriction confined to two or more areas of the 
cortex (figure 2D–F). Just over half the patients with sCJD had 
restricted diffusion in the thalamus in one of which the pulvinar 
signal was prominent.
In contrast, diffusion abnormalities, confirmed on ADC 
mapping, were virtually absent in the images from the non-prion 
cases being seen in only one case, a patient with cerebral 
lymphoma (figure 3) Two other patients, one with LGI1 anti-
body encephalopathy who had abnormal signal in the swollen 
left basal ganglion on DWI (figure 4) and the other had a pulvinar 
sign (figure 5) but ADC did not confirm restriction in either.
table 2 Final diagnoses in the patients proven not to have CJD





Definitive diagnosis 8 3 4 4 5 1 1 0
Clinical and investigation 
evidence
7 11 0 1 0 3* 1 1
*one case had SSPE
AD, Alzheimer’s disease; CJD, Creutzfeldt-Jakob disease; CVA, cerebrovascular accident; DLB, dementia with Lewy body disease including one case of frontotemporal dementia/
motor neuron disease; PML, progressive multifocal leukoencephalopathy; SSPE, subacute sclerosing panencephalitis.
table 3 Summary of symptoms and signs in patients with CJD and non-CJD
diagnosis dementia % hallucinations % Myoclonus % rigidity % Ataxia %
Definite sCJD 
(214 patients)
99 70 79 72 74
Not CJD 
(50 patients)
94 49 51 64 72
Fisher’s exact test P=0.048 P=0.008 P<0.001 P=0.30 P=0.85
CJD, Creutzfeldt-Jakob disease; sCJD, sporadic CJD.
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No case of CJD had gadolinium enhancement or haemor-
rhage but this did occur in one case of leukaemia with cortical 
infiltration.
Cerebrospinal fluid examination
CSF protein levels were normal or moderately elevated <1.0 g/L) 
in both groups of patients (table 4B). The CSF was always 
acellular (<2×106 cells/L, usually completely acellular) in the 
patients with sCJD. Three patients with inflammatory condi-
tions there were more than 4×106 cells per L.
The 14-3-3 and elevated S100B proteins were detected in 
both groups of patients but significantly more frequently in the 
patients with sCJD, the 14-3-3 protein being a marginally better 
discriminant. The RT-QuIC, which was determined in 35% of 
the patients, was invariably negative in the patients with an alter-
native diagnosis and positive in 89% of the patients with sCJD.
EEG
The first EEG obtained did not discriminate between the two 
groups with the exception of the presence of periodic complexes 
which were found in about a third of patients with sCJD 
(table 4C). However, a similar proportion of the non-CJD cases 
had sharp components superimposed on slow waves variously 
reported as epileptic discharges or evolving periodic complexes. 
In most cases only one EEG was obtained.
dIscussIOn
Of the neurodegenerative disorders, sCJD is a rare diagnosis. 
Most general neurologists in the UK will only see a case of 
sCJD every 1–5 years and without a highly specific test, diag-
nosis has relied on criteria primarily designed for epidemiology 
research to distinguish between probable sCJD and other more 
table 4 Investigation results: (A) MRI, (B) CSF, (C) EEG
A.MrI
diagnosis normal (%) Atrophy (%)
either bG and/or 
cortex* (%) bG and cortex* (%) bG alone* (%) cortex alone* (%)
CJD 12/171 (7) 70/178 (40) 158/171 (92) 112/171 (66) 13/171 (8) 33/171 (19)
Not CJD 9/47 (19) 26/47 (55) 2/47 (4) 0 1/47 (2) 1/47 (2)
Fisher’s exact test P=0.02 P=0.07 P<0.001 P<0.001 P=0.31 P=0.003
b.csF
Group 14-3-3 present (%) s100b elevated (%) rt-QuIc (%)
sCJD 112/130 (86) 108/128 (84) 67/75 (89)
Other diagnosis 13/25 (48) 12/18 (67) 0/25 (0)
Fisher’s exact test P<0.001 P=0.094 P<0.001
c.eeG
Group normal (%) slow waves (%) PsWc (%)
sCJD 11/186 (6) 154/186† (83) 67/186 (36)
Other diagnosis 5/40 (13) 25/40 (63) 2/40‡ (5)
Fisher’s exact test P<0.17 P=0.009 P<0.001
*Refers to the consensus opinion of a consultant neuroradiologist and consultant neurologist about the diffusion-weighted images of the BG or cerebral cortex.
†Includes patients who had PSWC.
‡One patient had SSPE type complexes, the other hepatic encephalopathy.
BG, basal ganglia; CJD, Creutzfeldt-Jakob disease; sCJD, sporadic CJD; PSWC, periodic sharp wave complexes; SSPE, subacute sclerosing panencephalitis. 
Figure 2 Different MRI sequences in patients with definite sCJD showing 
the value of DWI confirmed on ADC measurement compared to FLAIR. 
Images A–C illustrate typical basal ganglia abnormalities on FLAIR (A), 
DWI (B) and ADC (C). Images e and F show typical features of ‘cortical 
ribboning’ in the frontal and parietal cortex on FLAIR (D), DWI (e) and ADC 
(F) sequences. ADC, apparent diffusion coefficient; DWI, diffusion-weighted 
images; sCJD, sporadic Creutzfeldt-Jakob disease.
Figure 3 MRI in patient with cerebral lymphoma. Note patchy restricted 
diffusion in the posterior cortex (A) with partial confirmation on ADC 
(B) together with abnormal signal in the periventricular area and white 
matter on FLAIR (C). These areas corresponded to leptomeningeal nodular 
enhancing soft tissue. ADC, apparent diffusion coefficient.
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common neurodegenerative disorders. Prior to 2010, these 
criteria depended on the rapidity of the cognitive decline, the 
presence of myoclonus, ataxia, alteration of the signal in the 
basal ganglia on MRI using initially FLAIR and diffusion restric-
tion, the detection of 14-3-3 protein in the CSF and that no 
alternative diagnosis has been found. More recently, the MRI 
criteria have been extended to abnormality of cortical signal on 
DWI from two or more areas.3 These criteria have been used 
throughout the period over which the patients in the present 
report were studied. However, after the completion of this study, 
the RT-QuIC, using a variety of methods, has been added to the 
criteria and its presence is considered sufficient to make a diag-
nosis of probable sCJD in any neurodegenerative syndrome;10 
this parameter has been obtained retrospectively in a proportion 
of the patients in whom a CSF sample obtained in the appro-
priate container existed after the test became clinically available 
in the present study. Our study was not designed or statistically 
powered to consider diagnostic test performance in pathological 
and Western blot defined subgroups of CJD.
This paper shows that neurologists were successful in accu-
rately diagnosing sCJD in most cases in this series. Nevertheless, 
the delay in diagnosis was substantial the median time being over 
3 months in a disease where 50% of patients die within 5 months 
(table 1). This probably reflects multiple effects, including 
non-specific initial symptoms, the reluctance of clinicians to 
make a diagnosis for which there is no treatment, misinterpreta-
tion of the MRI and the delay in obtaining certain results partic-
ularly immunological tests. In the UK, most patients who have 
sCJD are screened for paraneoplastic antibodies and many have 
whole body FDG PET seeking occult neoplasia. In this series, 
there were five patients with such antibodies; in the three with 
LGI1 antibodies, all were diagnosed after referral on the clinical 
picture with faciobrachial seizures, a clinical picture that never 
occurred in patients with sCJD. The other two patients (one 
with PERM due to GLY1R antibodies, the other with NMDA 
antibodies) did have features likely to be confused with sCJD. 
Genetic studies that included a search for the commoner muta-
tions causing cognitive decline revealed three patients with muta-
tions; there were pointers to the correct diagnosis in all three 
(C9orf72 and CSF1R) on neurophysiology testing and MRI.
Distinguishing sCJD from DLB and AD can be difficult, 
particularly in those patients with rapid cognitive decline. It 
is thus not surprising that these two diagnoses were the most 
frequent mimics of sCJD in the present series. Focal atrophy of 
the hippocampi and/or parietal region on MRI and dopamine 
reuptake scanning was of some help in separating patients with 
AD, including those with a more posterior cortical picture, and 
DLB from those with sCJD. More recently, CSF measurement of 
the tau/amyloid β protein ratio has been shown to have a high 
sensitivity for diagnosis of AD but was not assessed in most of 
the cases in this series.15 Similarly, amyloid beta ligand PET was 
not in routine clinical use during the course of this study.
It is clear that the MRI of the brain is the most useful test 
with which to screen any patient who has a clinical picture that 
could be due to sCJD. MRI is usually rapidly available in hospi-
tals and a DWI sequence can be obtained even in a disturbed 
patient because acquisition times are short. Restricted diffusion 
confirmed on ADC mapping in the present series had a sensi-
tivity of 93% and a specificity of nearly 100% (one case had 
of lymphoma had partial confirmation of restriction). Unfortu-
nately, the classical features of sCJD with restricted diffusion in 
the cortex, basal ganglia and thalamus are often not detected by 
the radiologist outside specialist centres, thus delaying a diag-
nosis and a fruitless search for an alternative.5 Conversely, if 
basal ganglia or cortical signal abnormality is detected but asso-
ciated with parenchymal swelling, alternative diagnoses such as 
encephalitis or lymphoma should be considered: parenchymal 
swelling is not a feature of sCJD MRI. We show that over-re-
liance on the detection of the 14-3-3 proteins in the CSF can 
result in an incorrect diagnosis of sCJD as this is a non-specific 
marker of neurodegeneration.
The recent introduction of the various forms of RT-QuIC into 
clinical practice promises to make the clinical diagnosis of sCJD 
more secure.16–18 In this series, this test was never positive in the 
cases that were proven to have an alternative diagnosis and had 
Figure 4 MRI in patient with autoimmune encephalopathy due to LGI1 
antibodies. Note the high signal return from the swollen left basal ganglia 
on T2 (A), FLAIR (B) and DWI (C) sequences but restriction is not confirmed 
on ADC mapping (D). ADC, apparent diffusion coefficient; DWI, diffusion-
weighted images; LGI1, Leucine-rich, glioma-inactivated antibodies-1.
Figure 5 MRI in a patient with autoimmune encephalopathy due to 
NMDA antibodies is similar to the scans seen in vCJD. Note pulvinar sign 
on FLAIR (A) and DWI (B). The ADC scan did not confirm restriction (C). 
There is minor periventricular high signal in the FLAIR sequence (A). ADC, 
apparent diffusion coefficient; DWI, diffusion-weighted images; NMDA, 
N-methyl-D-aspartate antibodies.
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an extremely high sensitivity for detection of sCJD (87%). These 
results are consistent with published series revealing a sensitivity 
of between 82% and 96% and very high specificity presumably 
reflecting the different forms of recombinant protein used and 
biological factors of the patients such as distribution of codon 
129 genotype.9 18 19 Finally, in this paper, no patient with defi-
nite CJD had a combination of a negative RT-QuIC and negative 
DWI sequences on MRI.
cOnclusIOn
In practical terms, we suggest that the MRI using DWI sequences 
should be obtained in all patients who have a story of a rapidly 
progressive neurological syndrome. Restricted diffusion in the 
basal ganglia and/or more than one cortical region, absence 
of gadolinium enhancement, with sparing of the white matter 
points strongly to a diagnosis of sCJD in a patient with an 
appropriate clinical picture. The RT-QuIC should be obtained 
on the CSF in all those with features compatible with sCJD and 
especially those with a scan suggestive of that diagnosis. While 
overall diagnostic accuracy now appears to be excellent, we still 
make early diagnoses in a small proportion, largely because of 
delays in the initial suspicion of CJD. Hopefully direct detection 
of abnormal prions in peripheral biofluids like blood or urine 
will ultimately simplify the diagnosis of sCJD a situation that 
may have been achieved with vCJD.20–22
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